Latest Insider Transactions at Perrigo CO PLC (PRGO)
This section provides a real-time view of insider transactions for Perrigo CO PLC (PRGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PERRIGO Co plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PERRIGO Co plc's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 04
2024
|
Triona Schmelter EVP & President CSCA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,034
-23.3%
|
$24,816
$24.93 P/Share
|
Oct 04
2024
|
Triona Schmelter EVP & President CSCA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,611
+44.27%
|
$86,664
$24.93 P/Share
|
Sep 13
2024
|
Katherine C. Doyle Director |
SELL
Open market or private sale
|
Direct |
8,954
-59.84%
|
$241,758
$27.3 P/Share
|
Aug 26
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Open market or private sale
|
Direct |
13,000
-38.74%
|
$377,000
$29.4 P/Share
|
Aug 20
2024
|
Svend Andersen EVP & President CHCI |
SELL
Open market or private sale
|
Indirect |
6,683
-48.84%
|
$180,441
$27.43 P/Share
|
Aug 20
2024
|
Svend Andersen EVP & President CHCI |
SELL
Open market or private sale
|
Direct |
28,300
-14.86%
|
$764,100
$27.66 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,254
-15.54%
|
$411,858
$27.16 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
BUY
Grant, award, or other acquisition
|
Direct |
11,837
+19.24%
|
$319,599
$27.16 P/Share
|
Jul 10
2024
|
Patrick Lockwood Taylor CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,326
+36.71%
|
$764,802
$27.16 P/Share
|
Jul 08
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
479
-2.53%
|
$11,975
$25.72 P/Share
|
Jul 08
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
920
+4.63%
|
$23,000
$25.72 P/Share
|
Jun 07
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,104
-6.67%
|
$28,704
$26.94 P/Share
|
Jun 07
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,532
+21.48%
|
$117,832
$26.94 P/Share
|
May 28
2024
|
Svend Andersen EVP & President CHCI |
BUY
Open market or private purchase
|
Direct |
1,000
+0.97%
|
$27,000
$27.9 P/Share
|
May 15
2024
|
Erica L Mann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-19.42%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Erica L Mann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+28.8%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.46%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Jeffrey B Kindler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.36%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-36.23%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Albert Manzone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+43.01%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Adriana Karaboutis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.76%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Adriana Karaboutis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.72%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Bradley A Alford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-10.46%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Bradley A Alford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+17.89%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Orlando D Ashford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,259
-25.05%
|
$157,770
$30.22 P/Share
|
May 15
2024
|
Orlando D Ashford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,955
+34.29%
|
$328,650
$30.22 P/Share
|
May 15
2024
|
Katherine C. Doyle Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-21.95%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Katherine C. Doyle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+31.37%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Donal O'Connor Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-14.17%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Donal O'Connor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+22.79%
|
$262,920
$30.22 P/Share
|
May 15
2024
|
Geoffrey M. Parker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-17.19%
|
$126,210
$30.22 P/Share
|
May 15
2024
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+26.37%
|
$262,920
$30.22 P/Share
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-5.26%
|
$33,930
$29.69 P/Share
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,249
+9.18%
|
$65,221
$29.69 P/Share
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-3.45%
|
$32,625
$29.69 P/Share
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+6.22%
|
$62,727
$29.69 P/Share
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
886
-2.57%
|
$25,694
$29.69 P/Share
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,942
+7.87%
|
$85,318
$29.69 P/Share
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-2.84%
|
$15,254
$29.69 P/Share
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,746
+8.61%
|
$50,634
$29.69 P/Share
|
Mar 07
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
5,468
+5.14%
|
$158,572
$29.69 P/Share
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-4.38%
|
$25,620
$28.09 P/Share
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+7.76%
|
$49,252
$28.09 P/Share
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-2.92%
|
$25,620
$28.09 P/Share
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+5.31%
|
$49,252
$28.09 P/Share
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-2.15%
|
$19,404
$28.09 P/Share
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+6.67%
|
$64,400
$28.09 P/Share
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,147
-9.34%
|
$32,116
$28.09 P/Share
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+22.26%
|
$98,504
$28.09 P/Share
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-6.11%
|
$19,488
$28.09 P/Share
|